A Food and Drug Administration advisory committee today voted to recommend an emergency use authorization of Pfizer’s COVID-19 vaccine for children age 5-11. The agency’s Vaccines and Related Biological Products Advisory Committee, by a 17-1 vote, agreed that the available evidence justifies the administration of two 10-microgram doses, administered three weeks apart, particularly among those at the highest risk of severe COVID-19.

Related News Articles

Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Medicare & Medicaid Services Oct. 22 released final guidance detailing reporting requirements for the hospital respiratory data condition…
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Headline
The National Institutes of Health Oct. 10 released results of a study that found that infection from COVID-19 in the first wave of the pandemic appeared to…
Chairperson's File
Autumn is here, and that means cooler weather and also the start of flu season.We know the best way to prevent influenza is to get a flu vaccine. The Centers…
Headline
The National Foundation for Infectious Diseases Sept. 25 released a survey showing that less than one in five U.S. adults are concerned about themselves or a…